Filing Analysis
NanoViricides, Inc. entered into an 'at the market' (ATM) sales agreement with D. Boral Capital LLC on July 17, 2026. This allows the company to issue and sell common stock directly into the market to raise capital.
🚩 Red Flags
- Potential for immediate share dilution as the company can issue new common stock at market prices to raise cash.
📋 Key Facts
- Entered into an At Market Issuance Sales Agreement with D. Boral Capital LLC on July 17, 2026.
- The offering will be conducted via an 'at the market' (ATM) program under an existing S-3 shelf registration statement.
- Sales Agent (D. Boral Capital LLC) will receive a commission of 2.0% of aggregate gross proceeds from each sale.
- Shares may be sold on NYSE American or through other trading markets/privately negotiated transactions with company consent.
NanoViricides, Inc. disclosed comments made by its President and Executive Chairman, Dr. Anil R. Diwan, during a fireside chat at the Alliance Global Partners Healthcare Companies Showcase on May 20, 2026. Dr. Diwan discussed the potential efficacy of the company's drug candidates, NV-387 and NV-387 encapsulating Remdesivir, against the current Ebolavirus Bundibugyo strain epidemic in the Democratic Republic of Congo.
🚩 Red Flags
- The company is promoting speculative drug efficacy claims for Ebola and Mpox based on animal models and theoretical encapsulation benefits before human clinical trials for these specific indications are completed.
📋 Key Facts
- Dr. Anil R. Diwan participated in a fireside chat at the AGP Healthcare Companies Showcase on May 20, 2026.
- NV-387 is entering a Phase II clinical trial against Mpox in the Democratic Republic of Congo (DRC).
- The company has developed an oral formulation of Remdesivir encapsulated inside NV-387 nanoviricide micelles.
- Both NV-387 and NV-387 with encapsulated Remdesivir are expected by the company to be effective against the current Ebola virus Bundibugyo strain in the DRC.
- The company currently has an active clinical site in the DRC for the treatment of Mpox patients.
NanoViricides, Inc. entered into a securities purchase agreement for a registered direct offering raising approximately $2.0 million in gross proceeds. The offering consists of 1,133,334 shares of common stock and 200,000 pre-funded warrants at $1.50 per share, accompanied by 1,333,334 common warrants with an exercise price of $1.75.
🚩 Red Flags
- Highly dilutive structure with 100% warrant coverage (1,333,334 common warrants accompanying 1,333,334 shares/pre-funded warrants).
- The company is restricted from issuing new shares for 30 days and using its At-The-Market (ATM) offering agreement for 10 days, indicating tight near-term financing constraints.
📋 Key Facts
- Registered direct offering closed on May 18, 2026, raising approximately $2.0 million in gross proceeds before fees.
- Issued 1,133,334 shares of common stock and 200,000 pre-funded warrants at an offering price of $1.50 per share/pre-funded warrant.
- Issued 1,333,334 accompanying common warrants with an exercise price of $1.75 per share, exercisable for three years starting six months from issuance.
- Placement agent D. Boral Capital LLC received a 7.0% cash fee and up to $50,000 in expense reimbursements.
- CEO Anil Diwan agreed to a 30-day lock-up period.
- Company agreed to file a resale registration statement for the warrant shares within 30 days.
NanoViricides, Inc. held its 2025 Annual Meeting of Stockholders on November 22, 2025. Shareholders approved the re-election of Anil Diwan as a Director, an advisory vote on executive compensation, and the ratification of EisnerAmper, LLP as the independent accounting firm.
📋 Key Facts
- Meeting held on November 22, 2025.
- Quorum consisted of approximately 61% of outstanding voting capital stock (7,906,820 common shares and 838,025 Series A Preferred Shares).
- Anil Diwan was re-elected as Class I Director for a term expiring in 2027.
- Shareholders approved the advisory vote on executive compensation.
- EisnerAmper, LLP was ratified as the independent accounting firm for the fiscal year ending June 30, 2026.
NanoViricides, Inc. completed a $6.0 million registered direct offering and concurrent private placement (PIPE) involving common stock and various warrants. The proceeds are intended for working capital and general corporate purposes.
🚩 Red Flags
- Significant potential dilution from multiple layers of warrants (Series A and B) totaling over 7 million shares.
- The inclusion of pre-funded warrants often indicates the investor required more exposure than a standard equity purchase allowed, typically due to regulatory or structural constraints.
- Company agreed to a 90-day standstill on issuing further equity or filing new registration statements.
📋 Key Facts
- Total gross proceeds from the Offering: approximately $6.0 million.
- Issued 1,970,000 shares of common stock at $1.68 per share.
- Issued pre-funded warrants to purchase up to 1,601,429 shares at $1.67999 per warrant.
- Issued Series A Warrants (up to 3,571,429 shares) exercisable at $1.75 in six months.
- Issued Series B Warrants (up to 3,571,429 shares) exercisable at $2.00 in six months.
- The offering closed on November 12, 2025.
- Placement Agent A.G.P./Alliance Global Partners charged a 7.0% cash fee plus expense reimbursements.
NanoViricides, Inc. announced employment extensions for its President and CFO effective July 1, 2025, alongside an amendment to a significant $3 million line of credit provided by the company's President/CEO, Dr. Anil Diwan.
🚩 Red Flags
- Significant related-party transaction: The President/CEO acts as the primary lender to the company via a $3M line of credit.
- Collateralization risk: Company assets (real property and equipment) are pledged as security for debt owed to the CEO.
- Concentration of control: Both key executive employment terms and the company's primary financing source are tied directly to Dr. Anil Diwan.
📋 Key Facts
- Dr. Anil Diwan (President) extended employment through June 30, 2026; base salary is $400,000 annually plus 10,204 shares of Series A Preferred Stock vesting quarterly starting Sept 30, 2025.
- Meeta Vyas (CFO) extended employment through June 30, 2026; monthly compensation is $10,800 plus reimbursement for up to 50% of health insurance costs ($2,500/month cap).
- The company's Line of Credit with Dr. Anil Diwan was previously increased from $2M to $3M on Sept 23, 2024.
- The Line of Credit is collateralized by an Open End Mortgage Deed on the company's real property and a Chattel Mortgage against equipment/fixtures.
NanoViricides, Inc. held its 2024 Annual Meeting of Stockholders on December 7, 2024. Shareholders approved the re-election of three directors and the ratification of EisnerAmper, LLP as the independent accounting firm.
🚩 Red Flags
- High number of 'Broker Non-Votes' (3,813,361 shares) across all director elections, suggesting a significant portion of held shares were not voted on for these specific positions.
📋 Key Facts
- Annual Meeting held on December 7, 2024.
- Quorum was established with 47.1% of outstanding voting capital stock present (6,096,059 common shares and 883,177 Series A Preferred Shares).
- Theodore E. Rokita, Makarand Jawadekar, and Brian Zucker were re-elected to the Board of Directors.
- EisnerAmper, LLP was ratified as the independent registered public accounting firm for the fiscal year ending June 30, 2025.
NanoViricides, Inc. announced the extension of employment agreements for its President, Dr. Anil R. Diwan, and Chief Financial Officer, Meeta Vyas, effective July 1, 2024.
🚩 Red Flags
- Retention of key officers via equity grants and salary structures in a micro-cap environment can sometimes signal difficulty in attracting new talent or high burn rate concerns, though not explicitly stated here.
📋 Key Facts
- Dr. Anil R. Diwan's term as President is extended through June 30, 2025, with an annual base salary of $400,000.
- Dr. Diwan was granted 10,204 shares of Series A Preferred Stock (fully vested as of June 30, 2024).
- Meeta Vyas's term as CFO is extended through June 30, 2025, under existing terms ($10,800 monthly cash compensation plus 129 shares of Series A preferred stock monthly).
- The CFO extension includes a new provision for reimbursement of up to 50% of health insurance costs (capped at $2,500/month).
- Dr. Diwan is eligible for 6 months of severance if terminated without cause.
NanoViricides, Inc. has updated its At-the-Market (ATM) offering agreement to name EF Hutton LLC as the sole sales agent, removing B. Riley Securities, Inc. The company maintains a shelf registration for up to $50 million in common stock issuances.
🚩 Red Flags
- Continuous dilution risk: The maintenance of a $50 million ATM facility allows for ongoing issuance of shares, which can dilute existing shareholders.
- Uncertainty of funding: The company notes that actual sales depend on market conditions and capital needs, indicating potential reliance on equity markets to fund operations.
📋 Key Facts
- Executed a new Sales Agreement on April 5, 2024.
- EF Hutton LLC is now the sole sales agent; B. Riley Securities, Inc. has been removed.
- The ATM offering allows for the sale of common stock up to an aggregate price of $50 million.
- The company will pay a 3% commission on gross sales price per share sold.
- Sales are made via an existing 'shelf' registration statement (Form S-3, No. 333-271706).
- Company is not obligated to make any sales under the agreement.
NanoViricides amended its license agreement with TheraCour Pharma to defer cash milestone payments until 'Revenue Events' occur and suspended requirements for maintaining an advance payment. Additionally, the company extended a $2 million line of credit provided by its CEO from December 2024 to December 2025.
🚩 Red Flags
- Liquidity Strain: Suspension of advance payments due to inability to 'raise sufficient capital' indicates significant cash flow constraints.
- Related-Party Financing: The primary source of liquidity is a $2M line of credit from the CEO, which is collateralized by company assets (real property and equipment).
- Deferred Obligations: Restructuring milestone payments to be contingent on revenue suggests the company cannot meet current cash obligations under original terms.
📋 Key Facts
- Amended License Agreement with TheraCour Pharma: Cash milestone payments are now deferred until 'Revenue Events' (e.g., R&D grants, commercialization profit) occur.
- Revenue Event Definition: Specifically excludes financing from equity, mortgage, or debt transactions; only allows up to 50% of recognized revenue to be used for payments at the time of payment.
- Line of Credit Extension: A $2,000,000 standby line of credit provided by CEO Dr. Anil R. Diwan has been extended from a maturity date of Dec 31, 2024, to Dec 31, 2025.
- Suspension of Advances: The requirement to maintain an advance with TheraCour (equal to two months of projected invoices) is suspended until the company raises sufficient capital.
- Collateral: The CEO's line of credit is collateralized by a mortgage on the company's real property and a chattel mortgage on equipment.
NanoViricides, Inc. held its 2023 Annual Meeting of Stockholders on January 13, 2024. Shareholders approved the re-election of Anil Diwan to the Board, advisory compensation votes, a Series A Preferred Stock grant for the President, and the appointment of EisnerAmper, LLP as independent auditors.
🚩 Red Flags
- Approval of a significant equity grant (10,204 Series A Preferred Shares) to the President/Chairman (Anil Diwan), which may be viewed as highly dilutive or related-party compensation.
📋 Key Facts
- Meeting held on January 13, 2024.
- Quorum was established with 48.2% of outstanding voting capital stock present.
- Anil Diwan re-elected as Class I Director for a two-year term expiring in 2025.
- Shareholders approved an award of 10,204 Series A Preferred Shares to Anil Diwan related to his employment extension.
- EisnerAmper, LLP ratified as the independent registered public accounting firm for fiscal year ending June 30, 2024.